Keybank National Association OH Takes $300,000 Position in Verona Pharma plc (NASDAQ:VRNA)

Keybank National Association OH bought a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,460 shares of the company's stock, valued at approximately $300,000.

Several other large investors have also modified their holdings of VRNA. GAMMA Investing LLC lifted its holdings in shares of Verona Pharma by 20.7% in the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock valued at $75,000 after buying an additional 276 shares during the period. EMC Capital Management raised its position in Verona Pharma by 3,400.0% in the fourth quarter. EMC Capital Management now owns 3,500 shares of the company's stock worth $163,000 after acquiring an additional 3,400 shares in the last quarter. Wrapmanager Inc. acquired a new stake in Verona Pharma in the fourth quarter valued at $207,000. Claro Advisors LLC purchased a new stake in shares of Verona Pharma during the 3rd quarter worth $209,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Verona Pharma during the 3rd quarter worth $219,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

VRNA has been the topic of a number of research analyst reports. Roth Mkm started coverage on shares of Verona Pharma in a report on Friday, January 10th. They set a "buy" rating and a $68.00 price objective on the stock. HC Wainwright lifted their price objective on Verona Pharma from $60.00 to $75.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Canaccord Genuity Group upped their target price on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their price target on Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Finally, Roth Capital set a $83.00 price objective on shares of Verona Pharma in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $69.14.

Remove Ads

Verona Pharma Price Performance

Shares of NASDAQ:VRNA traded up $4.86 on Wednesday, hitting $67.56. The company had a trading volume of 778,826 shares, compared to its average volume of 1,527,300. The company has a market cap of $5.46 billion, a PE ratio of -35.25 and a beta of 0.39. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma plc has a 52-week low of $11.39 and a 52-week high of $70.40. The business has a 50 day moving average of $57.72 and a 200 day moving average of $43.03.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.